Epithelioid Hemangioendothelioma

This is a rare type of tumor that starts in the veins of the body. It's made up of cells that line the blood vessels. Doctors aren't completely sure if it's a true tumor or just an overgrowth of tissue. It can sometimes come back locally, but usually doesn't spread to other parts of the body.

Condition

What people with Epithelioid Hemangioendothelioma report

Every report comes from a Lived member, sent anonymously.

Have you tried Watchful Waiting for Epithelioid Hemangioendothelioma?

NameHow it went

About Epithelioid Hemangioendothelioma

What It Is

Epithelioid hemangioendothelioma (EHE) is a very rare cancer that grows from the cells lining blood vessels. It belongs to the sarcoma family, cancers of the body's connective and supporting tissues. EHE can start almost anywhere, but it most often appears in the liver, lungs or bone, and about half of people already have tumors in more than one place when it is found. What sets EHE apart is how differently it behaves from person to person. In many people it grows slowly, stays stable for years and occasionally shrinks without treatment. In others it acts like a fast-growing sarcoma. It is usually diagnosed between ages 30 and 50, though children and older adults can have it. Despite the similar name, it is a different condition from epithelioid hemangioma, a noncancerous blood vessel growth.

Causes & Risk Factors

EHE is driven by a genetic change inside the tumor cells, not one a person is born with. In about 90% of cases, two genes (WWTR1 and CAMTA1) break apart and fuse together; in most of the rest, a different pair (YAP1 and TFE3) fuses instead. The fused gene keeps switching on growth signals the cell would normally control. Why this happens is unknown. No lifestyle factor, exposure or habit has been shown to cause EHE, and it is not passed down in families.

How It's Diagnosed

EHE is often found by accident, on a scan done for another reason, because many people have no symptoms at first. When symptoms do occur, they depend on where the tumors are: pain is the most common, followed by a lump, abdominal discomfort, cough or shortness of breath, weight loss, or a broken bone. Imaging scans (CT, MRI or PET) show where the tumors are and whether they have spread. The diagnosis itself needs a biopsy, usually a core needle sample. A pathologist looks at the cells under the microscope and tests for the gene fusion (or the protein it produces), which confirms EHE and separates it from look-alikes such as other cancers that have spread to the liver or lungs. Because EHE is easy to mistake for something else, experts recommend having the biopsy reviewed at a sarcoma center if it was first read elsewhere.

Treatment Options

There is no single standard treatment, and care is best planned by a specialist sarcoma team. The approach depends mostly on whether there is one tumor or many, and on whether the disease is growing or causing symptoms. For a single tumor, surgery to remove it completely is the treatment of choice and cures most people, roughly 70 to 80% in expert series. Radiation may be added if cancer cells are left at the edges, or used instead of surgery when an operation is not possible. EHE limited to the liver may be treated by removing part of the liver; for selected people whose liver tumors cannot be removed and whose cancer has not spread elsewhere, a liver transplant is an option. Smaller tumors can sometimes be destroyed with heat-based ablation or focused radiation instead. When EHE is in several places but causing no symptoms, the usual first step is active surveillance: regular scans without treatment, because the disease may stay stable for years and starting medicines early risks side effects without clear benefit. Treatment starts when tumors clearly grow, symptoms worsen or an organ begins to struggle. No medicine is approved specifically for EHE, and standard sarcoma chemotherapy works poorly for most people. The drugs with the most reported activity are mTOR inhibitors such as sirolimus, which block a cell growth pathway; they typically hold the disease steady for around a year, though some people benefit far longer. They are used off-label, so insurance coverage can be a hurdle, and clinical trials are encouraged. Pain from EHE can flare and may respond better to anti-inflammatory medicines than to opioids, so early involvement of a palliative care or pain specialist is part of good care.

What to Expect

The course of EHE is hard to predict. Many people live for years with stable disease and few symptoms, while a smaller group has disease that grows quickly despite treatment. Having EHE in several organs does not by itself mean a poor outlook. The clearest warning signs of more active disease are fluid building up around the lungs or in the abdomen, and ongoing fever, weight loss or fatigue. Follow-up is long-term. After surgery, experts suggest scans about every 6 months for the first 4 to 5 years, then yearly if things stay stable. People on surveillance have a similar rhythm, and living with scans while not starting treatment can feel unsettling. Because so few doctors see EHE, many people travel to a sarcoma center for decisions while getting routine care closer to home, and EHE patient advocacy groups offer contact with others who understand the disease.

When to Seek Help

See a doctor about persistent, unexplained pain, a growing lump, or a scan that shows an unexpected mass in the liver, lungs or bone, and ask for review by a sarcoma specialist if EHE is suspected. If you have EHE, contact your care team promptly about new or worsening shortness of breath, swelling of the abdomen, fevers, unintended weight loss, increasing fatigue or pain that is getting harder to control. These can mean the disease is becoming more active and may change the plan, even during surveillance.

Questions to Ask Your Doctor

  1. 1.Has my biopsy been reviewed by a sarcoma pathologist, and was the gene fusion tested?
  2. 2.Is my EHE in one place or several, and is it growing, stable or causing symptoms?
  3. 3.Is surgery or another local treatment an option for me, or is active surveillance the better first step?
  4. 4.If treatment becomes necessary, what are my medicine and clinical trial options, and how will we know they are working?
  5. 5.How often will I need scans, and which changes should prompt me to call before my next appointment?

Last reviewed • Oct 2026

Educational content, not medical advice.